FDA Weighs Lilly, Amgen Findings On Cancer Drugs
By Sara Stefanini · December 12, 2008, 12:00 AM EST
The U.S. Food and Drug Administration has asked an advisory committee to consider whether clinical studies by Amgen Inc. and ImClone Systems Inc. are strong enough to show that their respective...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login